c‐Met signaling promotes IL‐6‐induced myeloma cell proliferation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objectives: Hepatocyte growth factor (HGF) is a constituent of the myeloma microenvironment and is elevated in sera from myeloma patients compared to healthy individuals. Increased levels of serum HGF predict a poor prognosis. It has previously been shown by us and others HGF can act as a growth factor to myeloma cells in vitro although these effects have been moderate. We therefore wanted to investigate if HGF could influence the effects of interleukin (IL)‐6. Methods: Myeloma cell lines and primary samples were tested for the combined effects of IL‐6 and HGF in inducing DNA synthesis and migration. Expression levels of c‐Met protein were analysed by Western blotting and flow cytometry. Signaling pathways were examined by Western blotting using phosphospecific antibodies and a Ras‐GTP pull down assay. Results: HGF potentiated IL‐6‐induced growth in human myeloma cell lines and in purified primary myeloma cells. There was also cooperation between HGF and IL‐6 in induction of migration. There seemed to be two explanations for this synergy. IL‐6‐treatment increased the expression of c‐Met making cells HGF responsive, and IL‐6 was dependent on c‐Met signaling in activating both Ras and p44/42 MAPK by a mechanism involving the tyrosine phosphatase Shp2. Conclusions: The results indicate that besides from being a myeloma growth factor alone, HGF can also potentiate the effects of IL‐6 in myeloma proliferation and migration. Thus, c‐Met signaling could be a target for therapy of multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109 · cited 2×
“The Ras-MAPK pathway is a major regulator of cell proliferation, and has previously been shown to be important for myeloma cell proliferation in vitro and in vivo (30).”
BackgroundResultRetractedHuh, C.-G., Factor, V. M., Sánchez, A., Uchida, K., Conner, E. A., & Thorgeirsson, S. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306068101 · Cited by 750
Met provides essential signals for liver regeneration
Borowiak, M., Garratt, A. N., Wüstefeld, T., Strehle, M., Trautwein, C., & Birchmeier, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403412101 · Cited by 497
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways
Štefanová, I., Hemmer, B., Vergelli, M., Martin, R., Biddison, W. E., & Germain, R. N. (2003) · Nature Immunology · doi:10.1038/ni895 · Cited by 465 · cited 1×
“NSC-87877 is also known to inhibit the tyrosine phosphatase Shp1; however, Shp1 has been shown to negatively control receptor signaling (45), and even to reduce MAPK-activation in thyroid carcinoma and neurons (46, 47).”
BackgroundNicholson, S. E., De Souza, D., Fabri, L. J., Corbin, J., Willson, T. A., Zhang, J.-G., Silva, A., Asimakis, M., Farley, A., Nash, A. D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100135197 · Cited by 456
Interleukin-21 is a growth and survival factor for human myeloma cells
Brenne, A.-T., Baade Ro, T., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002) · Blood · doi:10.1182/blood.v99.10.3756 · Cited by 168 · cited 1×
“OH-2 and IH-1 were established in our laboratory as described previously (25, 26).”
Self-citationChemical Dissection of the Effects of Tyrosine Phosphorylation of SHP-2
Lu, W., Shen, K., & Cole, P. A. (2003) · Biochemistry · doi:10.1021/bi0340144 · Cited by 59 · cited 1×
“There is also evidence that the double phosphorylation of Shp2 on tyrosines 542 and 580 is important for full catalytic activity of Shp2 (44).”
Background
Cited by
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes
Thompson, C. A., Purushothaman, A., Ramani, V. C., Vlodavsky, I., & Sanderson, R. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.444562 · Cited by 322
The role of IL-11 in immunity and cancer
Xu, D. H., Zhu, Z., Wakefield, M. R., Xiao, H., Bai, Q., & Fang, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.004 · Cited by 134
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
“HGS can also potentiate impact of IL-6 on MM cell proliferation and migration [7].”
Background
Metadata
- Authors
- Hov, H., Tian, E., Holien, T., Holt, R. U., Våtsveen, T. K., Fagerli, U., Waage, A., Børset, M., & Sundan, A.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2009-02-19
- Volume
- 82
- Issue
- 4
- Pages
- 277-287
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W1989578744
- Cited by
- 54
- References
- 7
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: c‐Met signaling promotes IL‐6‐induced myeloma cell proliferation. https://app.cochat.ai/papers/10.1111/j.1600-0609.2009.01212.x
- The paper
- Hov, H., Tian, E., Holien, T., Holt, R. U., Våtsveen, T. K., Fagerli, U., Waage, A., Børset, M., & Sundan, A. (2009). c‐Met signaling promotes IL‐6‐induced myeloma cell proliferation. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2009.01212.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.